Key result
Discontinuing anticoagulation in cancer-associated thrombosis yields ~15 recurrent VTEs per 100 person-years within three months.
Why the study?
The optimal duration of anticoagulation in patients with active cancer and venous thromboembolism is unknown, and an adequate systematic review on recurrent VTE after anticoagulation discontinuation had not been performed.
Meta-Analysis (n=1,922)
Discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis is associated with a high rate of recurrent VTE, supporting current guidelines for continuous anticoagulation.
No takes yet. Share an insight, caveat, or question.
High early recurrent VTE risk after anticoagulation discontinuation in cancer-associated thrombosis cautions against stopping; confirms guidelines for indefinite therapy.
Vlieg et al. (2023) conducted a meta-analysis in Cancer-associated thrombosis (n=1,922). Discontinuation of anticoagulant therapy was evaluated on Rate of recurrent VTE after discontinuation of anticoagulant therapy (95% CI 6.5-22.8). Discontinuation of anticoagulation in cancer-associated thrombosis yielded a recurrent VTE rate of 14.6 per 100 person-years (95% CI 6.5-22.8) in the first 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: